Diaceutics
Fixing the Siloed Diagnostic Ecosystem

In the US today, up to 50 percent of patients with non-small cell lung cancer traverse a diagnostic journey of around four years from initial cough to accurate diagnosis and prescription of treatment due to hurdles in the diagnostic testing ecosystem. Enter Diaceutics, the high-growth healthcare tech company which provides the world’s leading pharma with an end to end solution for the launch of precision medicine diagnostics enabled by their proprietary diagnostic commercialization platform DXRX – The Diagnostic Network®.

Today, we have an extensive network of over 400 million patient records that allows us to dive deep into their individual diagnostic pathways and identify the loopholes to help them better access the right treatment

As the world’s first digital, scalable platform designed to eliminate the siloes within the diagnostic ecosystem, DXRX assists in extracting, analysing, and communicating the data that indicates where the problem lies at three different levels— individual disease, individual lab, and an individual physician level. The data required to delineate these are obtained from insurance companies, laboratories and Diaceutics’ own studies, a combination of which gives a holistic view of the current status of an individual patient, offering a precision lab experience. After identifying the issues at different levels, the platform further helps eliminate those hurdles with the help of several tools that clients can subscribe to. For instance, one of the company’s live projects involves 60 laboratories across the globe, which serves as the first domino of the network. In this project, DXRX is assisting the labs in understanding their capabilities and position in testing breast cancer and further offering training to help them interpret new scorings. DXRX also helps measure the improvement of the laboratories after they utilise the platform. Generally, it takes around 18 to 24 months to identify transformation in the laboratory processes, but Diaceutics makes it possible to ensure significant changes in six months. “Today, we have an extensive network of over 400 million patient records that allows us to dive deep into their individual diagnostic pathways and identify the loopholes to help them better access the right treatment,” mentions Peter Keeling, CEO of Diaceutics.

Diaceutics’ platform connects every essential stakeholder in this space; one of the most critical being the pharmaceutical companies that are always looking forward to launching new methods to support treatment. These companies often need to introduce new treatments and drive sales in a shorter time frame, and that’s where Diaceutics’ solution comes in handy. Its platform and insightful data enable pharma companies to communicate with the labs in no time. Moreover, these companies are investing in better testing, which requires a shift from the traditional business model, and Diaceutics has succeeded in achieving this. Besides, Diaceutics is able to identify and connect a large number of laboratories across multiple countries with their specific addresses that test for a disease. The third group that Diaceutics engages with is the physicians to help build an efficient lab physician interface. In a nutshell, the company is creating a connected ecosystem of pharmaceutical companies, physicians and laboratories to ensure that the patients are provided with the right treatment. Diaceutics is the sole provider of an integrator that focuses on precision testing in the industry, which differentiates it. The company is striving to eliminate the siloes that exist in the diagnostic space with regard to speed and accuracy. Its solutions provide the right information to the pharmaceutical clients to assist the doctors in the labs and consequently offer the right treatment to the patient in real time.
Keeling outlines one of the live projects that involved the launching of a new drug for breast cancer. Diaceutics provided a substantial amount of data to the client that efficiently indicated the potential diagnostic hurdles that the client could face in their journey. The company also reported that the hurdles could cost up to 30 to 40 percent of its market share in the first couple of years. Additionally, in the next stage of engagement, the team looked up for leading laboratories before launching the drug that could assist in the new types of test interpretation. To this end, Diaceutics utilised its platform to recruit 60 vital labs that offer breast cancer diagnoses across ten different countries and built an extensive network of laboratories. This helped the labs to communicate with each other and devise better outcomes. Diaceutics also introduced a digital training program for the labs to quickly impart training to enhance their capabilities in interpreting tests in a better and more accurate way.

Diaceutics solutions extend across cancer and nononcology including rare and infectious diseases as well as COVID-19 with the aim to continue expanding its reach deeper into new diseases to reach as many patients globally as possible. The expansion of the network will engage more labs and expand the interconnected network of doctors, patients, pharma companies, and laboratories. What’s interesting here is the capability of Diaceutics to fulfil its goals in one-third of the timeframe using its platform in an informed and data-driven manner.